fashion -WSS

fashion

author：fashion 2025-09-06 04:14:16 - browse：1231

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： The new shift in health care is toward less care

Wikipedia

knowledge

WSS

What will save rural psychiatry services? Higher Medicaid payments

Senate panel clears PBM, hopsital reforms

MoonLake credibility takes another hit with mid

Ambulance rides for just $100? Advisers want major billing fixes

Health insurers say they are turning to AI to cut costs, improve care

Diversify hospital leadership teams to protect BIPOC patient health

hotspot

fashion

Wikipedia

Alkermes shareholders re

MoonLake credibility takes another hit with mid

Wildfire smoke exposes gaps in outdoor worker protections

FDA approves Recor Medical high blood pressure device

Medical leaders decry Supreme Court decision on affirmative action

AI used to predict Covid

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Insmed lung disease drug hits target in key Phase 3 trial

Tori Bowie and the unacceptable rates of Black maternal death

More doctors should go into startup world

focus

Childbirth

Addiction doctors spar with methadone clinics over legislation

Free speech concerns arise in wake of journal editor Eisen's firing

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Just how powerful is the placebo effect?

knowledge

knowledge

leisure time

focus